Catalyst Wire Dossier Catalyst Wire Dossier

S-1226 (8%)

S-1226 · SolAeroMed Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for S-1226 (8%), covering 2019-02-18 to 2019-02-18. Get the full timeline:

Most recent: Clinical Trial Update: Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma [Phase 2]

See pricing